"We have a glomerular disease recognition-to-referral [section], which is intended to guide general nephrologists, clinicians, even internal medicine doctors, on how to recognize an active glomerular disease, what tests to start taking on these patients, and when to make referrals," Vasquez-Rios said.
The compendium also curates landmark studies and clinical trials, an intentional response, he said, to how much is now being published in a field where clinicians have little time to keep up.
Access is a recurring theme because several glomerular disease therapies are highly effective but complex to prescribe. Thus, the compendium includes practical guidance on prior authorizations, referrals, and appeals.
"We provided tips and tricks to navigate these issues all the way from prior authorizations, referrals, appeals, and even provide some documentation that can help busy clinicians with this aspect of care," Vasquez-Rios said.
Inside the GD-C Compendium
- Condition-specific sections: ANCA-associated vasculitis, IgAN, lupus nephritis, C3G, membranous nephropathy
- A recognition-to-referral pathway for general clinicians
- Curated landmark studies and emerging clinical trial data
- Practical guidance on prior authorization, referrals, and appeals
- Patient education materials, with an evolving effort to incorporate patient voices directly
Built to Serve General Clinicians and GN Specialists Alike
Vasquez-Rios described the compendium as intentionally built for 2 different audiences with 2 different sets of questions. A general nephrologist or primary care physician, he said, is often asking whether a case is a glomerular disease at all, how active it appears to be, and how to begin testing or management. A GN specialist is typically further along, asking what the latest therapies are, what evidence supports them, and how to monitor a patient's response.
"What we're trying to do with this compendium is try to homogenize a little bit the management of these patients, regardless of where the point of entry to the healthcare system was," Vasquez-Rios said. "We recognize that glomerular disease patients are seen by a wide array of specialties, so it is important to have some practical foundations and information about how to approach these patients."
A Living Resource Designed to Evolve
The compendium is meant to function less like a static reference and more like a living resource clinicians return to, Vasquez-Rios said, with content he expects to update roughly every 6 months, faster for disease areas advancing quickly, such as IgAN and lupus nephritis.
"We're living a unique era in nephrology, especially in the management of glomerular diseases... there's a lot of unknowns as well in the management of these patients and the use of these medications," Vasquez-Rios said. "As therapies become available, we intend not only to include the scientific evidence, but also some practical information."
That update process, he said, is built around a feedback loop rather than a fixed editorial board, with contributions from physicians, general practitioners, GN experts from both community practice and academia, and researchers.
"That allows us to really build up more solid information... It’s all a process of learning, trial, error, learning again, and doing it better the next time," Vasquez-Rios said.
Editor's Note: Vasquez-Rios reports no relevant disclosures.
References
American Society of Nephrology. Glomerular Diseases Collaborative (GD-C) Compendium. Accessed September 17, 2026. https://epc.asn-online.org/projects/gd-c/
Monk B, Ewert B, Bomback AS, Gibson KL. Barriers to Patients Accessing Specialized Treatments for Glomerular Diseases. J Am Soc Nephrol. Published online July 14, 2025.